跳至主要内容
临床试验/2024-519383-40-00
2024-519383-40-00招募中3 期

Assessing Oxytocin's Role in Mitigating Psychosocial Stress in Breast Cancer Survivors

UZ Leuven1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2025年8月19日最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
发起方
UZ Leuven
入组人数
60
试验地点
1
主要终点
Assessments of self-perceived emotional stress, using the Dutch versions of the self-report Perceived stress scale (PSS) and the Depression Anxiety Stress Scale (DASS-42)

研究概览

简要总结

To examine whether administration of oxytocin can induce stress-regulatory effects in breast cancer survivors. Primary objective: Change from baseline after oxytocin administration on self-reported clinical-behavioral outcomes of psychological distress.

入排标准

年龄范围
18 years 至 65+ years(65+ Years, 18-64 Years)
性别
Female
接受健康志愿者

入选标准

  • Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.
  • Participants must be between 18 and 65 years old at the time of signing the Informed Consent Form (ICF).
  • Participants are eligible if they were diagnosed with breast cancer with or without solitary metastases (except solitary brain metastases), received chemo- and/or radiotherapy in the context of breast cancer management and ended this treatment 6 months to 6 years before enrollment. Patients who receive prolonged endocrine therapy or immunotherapy are eligible for participation in this study.
  • Participants have female biological sex.
  • Participants must have sufficient proficiency in Dutch to complete study tasks but do not need to be native speakers.

排除标准

  • Subjects who have had previous chronic treatment with oxytocin.
  • Patient has a significant active medical condition including hematological, endocrine, cardiovascular (including any rhythm disorder), respiratory, renal, hepatic, or gastrointestinal disease which influence the metabolism of oxytocin (IMP). Participants with a history of active epilepsy, defined as individuals experiencing seizures or requiring anticonvulsant therapy within the past 12 months, will be excluded from the study.
  • Being pregnant or breastfeeding, or planning to become pregnant.
  • Significant hearing or vision impairments (that cannot be corrected and that would interfere with the assessments).
  • Participation in another clinical trial with IMP (albeit not including clinical trials with endocrine therapy IMP).
  • Known hypersensitivity to active substance or ingredients in the nasal sprays, including e.g. (history of) latex allergy.
  • Use of the following medicinal products during the nasal spray administration period: prostaglandins and their analogues, inhalation anesthetics, vasoconstrictors/sympathomimetic drugs, or caudal anesthesia.
  • Current treatment with abemaciclib or ribociclib constitutes an exclusion criterion due to the known risk of QTc prolongation and potential drug interactions. Treatment with tamoxifen is permitted, provided that a baseline ECG shows no QTc prolongation; patients with QTc prolongation while on tamoxifen are excluded.

结局指标

主要结局

Assessments of self-perceived emotional stress, using the Dutch versions of the self-report Perceived stress scale (PSS) and the Depression Anxiety Stress Scale (DASS-42)

Assessments of self-perceived emotional stress, using the Dutch versions of the self-report Perceived stress scale (PSS) and the Depression Anxiety Stress Scale (DASS-42)

次要结局

  • Assessments of the following self-report questionnaires will be acquired as secondary end points: Cognitive Failure Questionnaire (CFQ), Checklist Individual Strength (CIS), Quality of Life (WHO-5), State Adult Attachment Measure (SAAM), Pittsburg Sleep quality index (PSQI), Perseverative Thinking Questionnaire (PTQ), and self-rated imression of severity and improvement (CGI).
  • Objective cognitive performance will be measured with the the digital Amsterdam Cognition Scan (ACS).

研究者

发起方
UZ Leuven
申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

Kaat Alaerts

Scientific

UZ Leuven

研究点 (1)

Loading locations...

相似试验